Long-term open-label extension trial for subjects completing the phase 3 trial of fesoterodine (SP584) for the treatment of overactive bladder syndrome.
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Adverse reactions
- Sponsors Pfizer; UCB
- 09 Apr 2008 Pfizer has replaced UCB Pharma as a trial sponsor, according to ClinicalTrials.gov.
- 18 Sep 2006 New trial record.